Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure

2012 ◽  
Vol 90 (1) ◽  
pp. 76-78
Author(s):  
Emma Lucy Neave ◽  
Heike Schwarb ◽  
Abdurrazag Shlebak ◽  
David Mark Layton ◽  
Jane F. Apperley ◽  
...  
Keyword(s):  
Post Transplantation ◽  
Donor Leukocyte Infusion

Dialysis and Renal Transplant in a Hemophiliac

1981 ◽  
Vol 46 (03) ◽  
pp. 626-628 ◽  
Author(s):  
Edward D Gomperts ◽  
Mohammed H Malekzadeh ◽  
Richard N Fine
Keyword(s):  
Renal Transplant ◽  
Post Transplantation ◽  
Home Hemodialysis ◽  
Post Transplant ◽  
Cadaver Donor

SummaryHemodialysis was initiated in a mild-moderate hemophiliac at 15 years of age. Hematuria had been a frequent and persisting feature from the age of five years without documented cause. Anemia and proteinuria was first detected at 13 years. A cadaver donor renal transplant was carried out after three months of hemodialysis. Massive intravesical bleeding complicated the immediate post-transplantation period. The allograft rejected after three months and the patient was maintained for eight years on home hemodialysis. A second cadaver donor allograft was carried out at 23 years of age. Again, massive intravesical hemorrhage was a problem post-transplant. The allograft is currently functioning 27 months post-transplant. Factor VIIIc activities have fluctuated between 5% and 40% in the absence of factor infusions.

POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW)

2019 ◽  
Vol 65 (3) ◽  
pp. 330-336
Author(s):  
Irina Gribkova ◽  
I. Ishmatova ◽  
Mariya Davydovskaya ◽  
K. Kokushkin
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Literature Review ◽  
Stem Cell Transplantation ◽  
Clinical Improvement ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Post Transplantation ◽  
Hematopoietic Stem ◽  
Graft Versus Host

The aim of the study was to systematize and summarize the current available data on ruxolitinib use in patients with myelofibrosis (MF) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) to improve its results. The review includes data from foreign and domestic articles found in the PubMed and elibrary.ru databases describing the results of the use of ruxolitinib in patients with MF prior to allo-HSCT, including clinical cases, original scientific studies and reviews. It is reported that ruxolitinib therapy is safe, reduces mortality in the early post-transplantation period, reduces the incidence of acute and chronic graft-versus-host disease, and decreases the frequency of relapses. Clinical improvement with ruxolitinib therapy prior to allo-HSCT can be considered a prognostically favorable factor.

Sign in / Sign up

Export Citation Format

Share Document